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Abstract 
 
Drug safety and pharmacovigilance have been brought to scrutiny of the public eye via 
the media through many recent marketed drug recalls and congressional hearings 
involving the Food and Drug Administration.  There is currently no formal education 
program, no professional certification and no list of core competencies for drug safety 
professionals in the US. This paper will review the literature of the science of drug 
safety, the current regulatory climate of drug safety and also examine the current 
resources for drug safety professionals to continue their education. This paper provides 
recommendations for a core set of competencies for drug safety professionals. 
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Title: Core Competencies for Drug Safety/Pharmacovigilance Professionals 
Problem and Literature Review 
 Over the past decade, the safety of marketed drugs has been brought to scrutiny 
of the public eye via mass media, through recalls of marketed drugs, congressional 
hearings involving the Food and Drug Administration (FDA), patient rights groups, and 
class-action law suits involving patients injured by drugs that are subsequently recalled 
or deemed restricted use.  These events have ultimately led to the FDA receiving 
heightened authority over marketed and investigational new drugs, and are also 
reflected in a decreased annual rate of new drug application approvals.²⁹ The regulatory 
climate for drug safety is currently similar in the European Union.³ 
 Adverse drug reactions (side effects) due to marketed drugs are on the continued 
rise and are now considered a public health epidemic. The U.S. FDA Sentinel Initiative 
report of 2008 reports that is it estimated that more than 2 million U.S. residents are 
harmed annually as a result of errors in the prescribing, selection, or use of 
prescriptions or over-the-counter drugs (medication error), or because patients 
experienced a side effect. It is estimated that up to 100,000 of these episodes result in 
death annually.³³  In 2007, unintentional drug overdoses of prescription opioids led to 
more deaths than unintentional drug overdoses of cocaine and heroin combined.⁶ 
Opioid analgesics Oxycodone, fentanyl, morphine, and methadone ranked among the 
top 6 most frequent suspect drugs of fatal serious adverse events reported to the US 
FDA’s spontaneous Adverse Event Reporting System (AERS) between 1998 and 
2005.²¹ Fatal adverse drug events increased 2.7-fold during the same period, from 5,519 
to 15,107 deaths.²¹  Out of the top 15 most frequent suspect drugs in fatal SAE reports 
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to AERS, seven of the drugs were for pain, four had primary effects on the immune 
system (including TNF inhibitors, interferons) and four were 
antipsychotics/antidepressants.  It is estimated that as few as 0.3% of SAEs that occur 
in the US are ever reported to the FDA or manufacturer, although some estimates are 
as high as 33%.²¹  
 When the FDA approves a new drug application, there is not always a robust 
safety profile in place due to the size of clinical trial populations – many types of 
adverse events are rare and therefore do not occur until drugs are given to a larger, 
more diverse population after market approval.²⁹ 
 Currently, there are no evidence-based practices for drug safety activities (i.e. 
activities that have been proven to improve safety of drugs and reduce adverse events). 
There is also no formal set of competencies for drug safety professionals. This is 
possibly due to industry viewing standard operating procedures and training programs 
as “proprietary”, in contrast with academic research organizations that are more likely to 
share knowledge and publish. While industry leaders may share drug safety knowledge 
and lessons learned at professional conferences, such as Drug Information Association 
(DIA) meetings, these success stories and "best practices" are not often published for 
the larger drug safety community to digest.   
  While some authors differentiate between professional skill sets needed to 
perform pre and post-approval pharmacovigilance activities¹, the Sentinel Initiative 
jointly issued by the US Department of Health and Human Services (DHHS) and US 
FDA in 2008 further defines and develops the science of drug safety with the adoption 
of a life-cycle approach to product development from the bench side to the bedside. 
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This life-cycle approach to pharmacovigilance will allow safety signals generated at any 
point in product development to be evaluated along with current benefit-risk data to 
better inform regulatory decision making.³³ 
Background and history 
 The FDA is the governmental agency primarily responsible for ensuring the 
safety and efficacy of marketed drugs and investigational new drugs in the US.  Over 
the previous century, a multitude of laws have been put into place to protect patients, 
with a number of acts and amendments generated and passed in reaction to adverse 
drug effects. Figure 1 provides a general timeline of events and corresponding laws 
regarding drug safety, though it is not meant to be an exhaustive list of all events, 
regulations and publications relevant to drug safety.³⁸ 
 
 There have been several high-profile adverse drug effects that have resulted in 
the creation and implementation of new laws or key amendments to existing laws. For 
example, sulfanilamide was associated with 107 deaths in 1937 and resulted in passing 
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the FD&C Act of 1938, which required new drugs to be shown as safe prior to 
marketing.³⁸ In 1961, thalidomide was associated with thousands of birth defects to 
babies born in Western Europe, and contributed to the passing of the Kefauver-Harris 
Drug Amendments Act of 1962 which required, for the first time, drug manufacturers to 
prove to FDA the effectiveness of their products before marketing them (FDA history 
timeline cite).³⁸ The Kefauver-Harris Drug Amendments resulted in a prolonged 
approval time for new drug applications (NDAs), two to three years by the last 1980’s. In 
1992, the Prescription Drug User Fee Act (PDUFA) was enacted by Congress in order 
to expedite NDA reviews. While PDUFA provided industry user fees to expedite review 
times by the FDA, the Act did not provide the FDA with additional authority to require 
drug sponsors to conduct safety studies post-approval and also did not provide the FDA 
with authority to order labeling changes to marketed drugs.²⁹  
 In 1997, Wyeth Pharmaceutical (formerly known as American Home Products) 
withdrew its diet drugs Pondimin and Redux from the market, after off label use of drug 
cocktail fenfluramine- phentermine (fen-phen) was shown to be associated with 
pulmonary hypertension and heart valve disorders. Over the next decade, about $20 
billion was paid out from the manufacturer for lawsuit settlements.³⁰   
 In 2000, the FDA issued a public health advisory warning that 
phenylpropanolamine (PPA), an ingredient found in common over-the-counter cold 
medications and dietary aids, may increase the risk of hemorrhagic stroke, and so 
should be avoided.³² The warning was based on results of a highly controversial case 
control study, the Hemorrhagic Stroke Project, by investigators at Yale University in 
collaboration with the FDA and PPA manufacturers, which was published in the New 
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England Journal of Medicine.¹⁷ The Consumer Healthcare Product Association, 
representing manufacturers, countered that the Hemorrhagic Stroke Project findings 
were not conclusive with regards to a causal relationship between PPA use and 
hemorrhagic stroke. They argued that cases and controls were not matched for 
confounding factors such as history of hypertension and/or family history of stroke, 
current smoking, current alcohol use and current illicit drug use, all of which were more 
prevalent among cases than controls.³⁹   In response to the request made by FDA in 
November 2000, many companies voluntarily reformulated their products to exclude 
PPA. In 1995, the FDA issued a proposed rule that reclassified PPA as non-monograph 
(Category II – not generally recognized as safe and effective).³²   
 In 2001, Bayer voluntarily removed Baycol (cerevastain) from the market due to a 
ten-fold higher frequency of reports of rhabdomyolysis as compared to five other statins, 
with highest risk to patients with the highest cerevastatin dose and with concomitant use 
of Lopid (gemfibrozil).¹⁰ The recall of cerevastatin was widely publicized, partially due to 
the fact that five other statins (lovastatin, pravastatin, simvastatin, atorvastatin, and 
fluvastatin) remained on the market and also due to the nature of the event: 
rhabdomyolysis is usually a very rare disorder caused by the rapid breakdown of 
muscle cells that overloads the kidneys and can cause renal failure and death.²²  As 
myagia (muscle pain) is an expected event for statins, but also a symptom of 
rhabdomyolysis, spontaneous AE reports by consumers and health care professionals 
to manufacturers and the FDA increased in volume. Heightened public awareness of 
potential AEs may have accounted for atorvastatin and simvastatin ranking among the 
top 15 suspect drugs (number 8 and 14, respectively) reported in non-fatal serious 
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adverse event reports to the FDA Adverse Event Reporting System (AERS) between 
1998 and 2005 ²¹.  
 In 2004, after more than 80 million patients had been prescribed Vioxx 
(rofecoxib) and annual sales were at 2.5 billion³¹, Merck issued a voluntary worldwide 
withdrawal of Vioxx (rofecoxib) from the market based on new, three-year data from the 
APPROVe study results which showed an increased relative risk for cardiovascular 
events (heart attack and stroke) beginning after 18 months of treatment with rofecoxib 
25 mg as compared to placebo.⁴⁰.  The VIGOR study completed in 2000 had also 
shown an increase risk of cardiovascular events with rofecoxib versus naproxen.  Merck 
stated that the phase III studies that were the basis for regulatory approval did not show 
an increase in risk of cardiovascular events.⁴⁰ Rofecoxib ranked as the 14th most 
frequent suspect drug named fatal SAE reports and the 6th most frequent suspect drug 
named non-fatal SAE reports to the spontaneous FDA Adverse Event Report System 
(AERS) between 1998 and 2005, part of which the volume of reports might be attributed 
to the highly publicized recall.²¹ Implications of the recall were great: in 2004 the FDA, 
Merck and rofecoxib were subject to US Senate hearings, questioning the continued 
promotion of rofecoxib and the delay in withdrawal of rofecoxib from the market from the 
time cardiovascular risks were first known by Merck scientists and the FDA’s not taking 
greater responsibility for the pharmacovigilance of the drug that they had approved.³¹ 
The withdrawal of rofecoxib resulted in a $4.85 billion dollar settlement with 47,000 
groups of plaintiffs.³⁰     
 The Food and Drug Administration Amendments Act (FDAAA) of 2007 was 
passed, which reauthorized existing laws: Prescription Drug User Fee Act (PDUFA), 
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Medical Devise Use Fee and Modernization Act (MDUFMA), Best Pharmaceuticals for 
Children Act (BPCA), Pediatric Research Equity Act (PREA), and also added new 
provisions to the FD&C Act by providing new authority to the FDA regarding 
postmarketing safety of drugs.³⁶ Specifically, Title IX of the FDAAA provided the FDA 
with authority to require sponsors to submit and implement Risk Evaluation and 
Mitigation Strategies (REMS) for NDAs if the FDA determines that a REMS is necessary 
to ensure the benefits of a drug outweigh its risks. The FDA may also require sponsors 
to conduct postmarketing safety studies in order to identify and assess serious drug 
risks, and order a labeling change after a 30-day period of negotiation.³⁶ Title VIII of 
FDAAA increased the requirements for clinical trial information posted on the public 
clinical trial registry (clinicaltrials.gov) including timely posting of clinical trial results by 
study sponsors.²⁹  The FDA initiated its REMS authority in 2008, by notifying sponsors 
of drugs deemed to have already in effect an approved REMS, through established 
elements to assure safe use that previously appeared in an approved risk minimization 
action plan (RiskMAPs). Also in 2008, the FDA initiated requirements of REMS in order 
to approve specific NDAs and notified sponsors with NDAs approved prior to the 
FDAAA that a REMS was required, due to “new safety information”.⁴¹ In 2009, the FDA 
met with opioid manufacturers to initiate development of REMS programs.¹⁶   
 The FDAAA also calls for development of methods to obtain access to disparate 
data sources and to establish a postmarket risk identification and analysis system to link 
and analyze healthcare data from multiple sources, with the goal of access to data from 
25 million patients by July 1, 2010 and to 100 million patients by July 1, 2012.³³ 
Accordingly, the FDA has launched the Sentinel Initiative – a national, integrated, 
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electronic system for monitoring product safety.³³ The Sentinel Initiative 2008 report 
indicated that the prior decade’s “increased focus on safety and quality was, in part, a 
result of the emerging science of safety, which combines a growing understanding of 
disease and its origins with new methods of signal detection, data mining, and analysis, 
enabling researchers to generate hypotheses about and confirm the existence and 
causal factors of safety problems in the populations using the products”.³³  
 The most recent major drug withdrawal/restricted use case was the suspension 
of Avandia (rosiglitazone) from the European market and restricted use announcement 
by FDA in 2010, after several years of analysis and controversy regarding the 
cardiovascular safety of the oral diabetes drug/ At the time, rosiglitazone was at $3 
billion/year in sales.⁴³’⁴⁴  Rosiglitazone was shown to increase the incidence of new 
heart failure and myocardial infarction, although the post-market study conducted by the 
sponsor (RECORD) did not show the same cardiovascular risk and was highly debated 
due to early unblinding and actual length of time patients were treated with 
rosiglitazone.⁴³’⁴⁴    
 Scrutiny on drug safety continues to increase, as indicated by the recent draft 
revisions to the FDA Code of Federal Regulations (CFR) 312.32 in the fall of 2010, with 
the ultimate goal of improving the overall quality of clinical safety reporting thereby 
strengthening the agency’s ability to review critical safety information, monitor the safety 
of human drug and biological products and harmonize safety reporting internationally.⁴²  
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 What comprises drug safety?  
 With the frame of reference of historical events and subsequent market 
withdrawals and increased regulatory authority, it is clear that a “safe drug” is an 
oxymoron.  The World Health Organisation (WHO) defines Pharmacovigilance (PV) as 
'the science and activities relating to the detection, assessment, understanding and 
prevention of adverse effects or any other drug-related problem'.³⁸ The WHO 
Programme for International Drug Monitoring was originally established in response to 
the thalidomide disaster in 1961. Currently, the WHO Collaborating Center for 
International Drug Monitoring Uppsala promotes pharmacovigilance at the country level 
with 134 current member countries. The goals of this program are to “enhance patient 
care and patient safety in relation to the use of medicines; and to support public health 
programmes by providing reliable, balanced information for the effective assessment of 
the risk-benefit profile of medicines”.³⁸  
 Comprehensive regulations exist for health authorities to monitor the safety of 
investigational new drugs and marketed drugs. The FDA Code of Federal Regulations 
(CFR) 312.32 IND safety reports, 312.64 Investigator reports, and 314.80 
Postmarketing reporting of adverse drug experiences provide definitions and reporting 
timelines for industry, to ensure that the FDA and study investigators will be informed of 
any unexpected serious suspected reactions by sponsors in a short timeframe.  
Globally, the International Conference on Harmonisation (ICH) provides comprehensive 
guidelines for managing safety both pre and post approval.⁴⁶ The European Union (EU) 
requires safety reporting per the European Commission law: Directive 2001/20/EC and 
Regulation (EC) No. 726/2004.⁴⁷’⁴⁸ 
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 As specifically detailed in its regulations, the FDA requires investigators to report 
to sponsors any serious adverse event that arises out of a clinical study, whether or not 
considered drug related, and investigators must include an assessment of whether 
there is reasonable possibility that the drug caused the event.⁴⁵ According to FDA CFR 
312.32, the FDA requires sponsors to submit expedited reports of serious adverse 
events that arise out of clinical trials for investigational new drugs to the FDA, if there is 
evidence to suggest a causal relationship between the drug and the serious adverse 
event and the serious adverse event is considered unexpected according to the current 
investigator’s brochure (labeling document).³⁵ These “IND Safety Reports” must be 
submitted to the FDA within 15 calendar days of initial receipt of the report by the 
sponsor company or its representative (e.g. contract research organization or country 
office), and the timeline for notifying the FDA is reduced to 7-calendar days for related 
unexpected serious adverse events that have a serious criteria of fatal or immediately 
life-threatening.³⁵ IND Safety Reports must also be submitted to active study 
investigators within 15 calendar days for an IND drug.³⁵ The corresponding expedited 
safety reporting regulation for marketed drugs, CFR 314.80, requires sponsors to 
submit individual case safety reports to the FDA for any reported serious adverse 
events that are unlabeled according to the US package insert within 15 calendar days of 
receipt of the report by the sponsor company or its representative.³⁴   
 The FDA CFR also specifies requirements for annual IND reports to be submitted 
for any compound under an active IND, providing details of any new adverse events 
and deaths.⁴⁶  There is also a requirement for drug manufacturers of both prescription 
drugs and over the counter drugs to submit periodic reports at pre-scheduled intervals 
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in order to present an overview of all the safety-related information reported during the 
reporting period.³⁴  The European Union and ICH provide requirements for reporting of 
adverse events from investigational new drugs and marketed drugs with very similar 
submission timelines as well as periodic safety update report (PSURs) requirements⁵⁰.   
 The FDA CFRs, ICH Efficacy Guidelines and the EU Directive 2001/20/EC 
provide definitions and terminology for drug safety, as well as timeframes for reporting. 
Appendix 1 provides a list of current definitions and drug safety terminology.   
Review of stakeholders: who is performing drug safety and who is reviewing?  
 There are many stakeholders with interest in monitoring the safety of 
investigational and marketed drugs to ensure patient safety and optimization of a drug’s 
risk-benefit profile.  
 Sponsors, including pharmaceuticals and biotechnology companies, are 
responsible for performing safety monitoring for their investigational new drug studies. 
These activities includes design of collection and reporting processes for both non-
serious and serious adverse events, which should be detailed in the study protocol and 
safety reporting plan, and design of a serious adverse event (SAE) report form to be 
consistent with  variables included on the clinical study case report form adverse event 
page. The sponsor also should set up and validate the safety database and register with 
EudraVigilance for electronic reporting (for studies conducted in the EU), train study 
investigators, study coordinators and study monitors/clinical research associates 
(CRAs) on AE and SAE reporting instructions. Once patient enrollment begins, 
sponsors will process any SAE reports, including writing of clinical narratives, coding of 
adverse events, medical monitor evaluation and determination of company causality 
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and expectedness assessment, and practice of due diligence with timely follow-up 
requests or queries to the reporting investigative site for additional information and 
clarification. For reports of SAEs that meet the expedited reporting requirements to 
health authorities (as per applicable regulations), sponsors must submit these reports to 
the FDA (and other health authorities) within 7 and/or 15-calendar days from initial 
receipt of the report from the investigative site. Sponsors are also responsible for 
sending these reports to central and local ethics committees (where required) and all 
investigators within 15-calendar days from initial receipt. Sponsor medical monitors 
perform signal detection though regular reviews of safety and clinical database listings, 
patient vital signs, laboratory data, and other available clinical information in order to 
assess for potential safety signals. Sponsors must submit annual IND reports to the 
FDA and bi-annual and annual safety reports in the EU for studies conducted in these 
respective countries. Many of these safety activities are often outsourced by sponsors 
to a global contract research organization that is performing other services for the 
sponsor, such as site monitoring and data management.  
 There are many other responsible parties involved in ensuring patient safety in 
clinical trials with investigational new drugs. Study investigators are responsible for 
following good clinical practices when enrolling and treating patients in clinical trials and 
for reporting any serious adverse events to the sponsor immediately (with the exception 
of study endpoints that must be recorded in accordance with the protocol).⁴⁵ Institutional 
review boards (IRBs) and ethics committees (ECs) are responsible for patient safety 
and conduct of clinical trials at the universities, hospitals and research clinics that they 
oversee. IRBs/ECs are responsible for approval of new research protocols and receive 
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reports of serious adverse events from sites at their institutions. Data and safety 
monitoring boards (DSMBs) or data monitoring committees (DMCs) are also 
responsible for monitoring the safety of investigational new drugs through independent 
review of unblinded safety data at specified timepoints in the study to ensure the safety 
of the patients in clinical studies.  
 Health authorities are responsible for the safety of investigational new drugs and 
perform comprehensive activities in support of safety. Health authorities review study 
protocols and provide feedback, receive expedited reports of serious adverse events, 
and perform inspections or audits of sponsors clinical trial records and documentation to 
ensure compliance with good clinical practices and the code of federal regulations.  
 Sponsors, such as pharmaceutical and biotechnology companies, are 
responsible for monitoring the safety of their drug once it has been approved for market 
use. In order to fulfill postmarket safety reporting regulations, sponsors are required to 
have in place a pharmacovigilance, drug safety, or medical affairs department to 
receive, triage, process, evaluate and report adverse events reported from marketed 
use. Sponsors collect spontaneous reports of adverse events from consumers and 
health care professionals usually through a call center that receives calls from a toll-free 
phone number that is included on medication bottles or labeling information. Sponsors 
also receive reports of adverse events on marketed drugs through a variety of other 
sources, including sponsor sales representatives, solicited information from patient 
programs (such as discounted drug plans), and post-market (phase IV) studies. 
Sponsors conduct routine literature searches for reports of adverse events with their 
marketed drugs in published manuscripts. Sponsors receive reports from other 
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pharmaceuticals for co-suspect or co-licensed drugs, and also receive secondary 
reports from health authorities. In addition to performing expedited safety report 
submissions (15-day reports) to the FDA for any reports of serious adverse events that 
are unlabelled according to the package insert (CFR 314.80), sponsors are responsible 
to perform periodic reporting to the FDA, providing cumulative adverse event reports for 
the reporting interval. Sponsors perform analysis, data mining and signal detection for 
the adverse events reported for their marketed drugs, usually utilizing their global safety 
database. They also create and maintain risk management plans (RMPs) and if 
applicable, risk evaluation mitigation strategies (REMS) for their marketed drugs.  
 Health care professionals share in the responsibility for ensuring continued safety 
of marketed drugs, through spontaneous reports of adverse events to sponsors or 
health authorities. Physicians and pharmacists should report adverse events that their 
patients experience through the FDA reporting MedWatch system. Health authorities 
bear great responsibility in receipt and review of analysis of expedited safety reports, 
periodic adverse event reports, and reports from consumers and healthcare 
professionals through the MedWatch reporting system. Health authorities also perform 
inspections at sponsor companies to ensure compliance with FDA CFR 314.80 and 
other regulations.       
Examination of the current drug safety training programs 
 Currently, no formal expectations for professionals working in pharmacovigilance 
exist, in regards to training and drug safety topics.⁹ There is no formal certification or 
accredited education program in the US for pharmacovigilance professionals. In many 
countries the field of pharmacovigilance is relatively new and the need for highly skilled 
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professionals is great.¹ In India, for example, where large pharmaceuticals have 
outsourced volumes of post-marketing safety work, it was noted that there are not many 
resources available, including the internet, literature or books, to provide new drug 
safety professionals with the requirements for setting up and maintaining a competent 
pharmacovigilance department.¹   
 Europe is more advanced in development of formal drug safety training programs 
as compared to the rest of world.  The Drug Safety Research Unit (DSRU) in the UK 
recently established a post-graduate certificate program, post-graduate diploma, and 
master of science programs in Pharmacovigilance. These courses are directed towards 
professionals already working in pharmacovigilance or related areas.²⁰ There is a 
EudraVilance user training program for electronic reporting of individual case safety 
reports  (ICSRs) in the European Economic Area (EEA), offered primarily in London by 
the European Medicines Agency (EMA) in coordination with the Drug Information 
Association (DIA), which is the only training program officially recognized by the 
European Medicines Agency.⁵¹ Participants that pass the competency assessment 
following the course will receive a certificate that will allow them to register with 
EudraVigilance and to report ICSRs to the European Medicines Agency and/or the 
National Competent Authorities in the EEA.⁵¹ The EudraVigilance training program is 
geared mainly towards training safety professionals how to perform data entry or 
electronic submission of ICSRs to the EVWeb, an affordable alternative to setting up 
E2B-compliant transfer modules in sponsor databases.⁵¹   The DIA held a 
Pharmacovigilance and Risk Management Strategies Conference early in 2011, which 
Page 18 of 35 
 
reviewed current complexities and controversies of drug safety and risk management 
throughout all stages of drug development and marketed use.⁵²  
Applying the literature review to the problem  
 There is much literature regarding the practice of public health and core 
competencies for public health professionals. As of 2010, more than 50% of state and 
local health departments and more than 90% of public health academic institutions 
utilized Core Competencies for Public Health Professionals to identify and meet 
workforce development needs.²⁸  
 In contrast, there is a lack of publication on the topic of drug safety or 
pharmacovigilance core competencies.  A PubMed search for “drug safety core 
competencies” and “drug safety competencies” produced 13 results, mostly topics of 
prescribing competencies.  Two articles had topics of pharmacy student-driven 
detection of adverse reactions in the community pharmacy setting.⁷ A search for 
“pharmacovigilance core competencies” produced 0 results.  Search for 
“pharmacovigilance competencies” produced 4 results, one of which was a white paper 
on the topic at hand. Edwards, et. al. described in 2006 that the absence of accepted 
pharmacovigilance competencies was a key factor that hindered the development of 
training and curriculum programs.⁹ The authors go on to describe a theoretical model of 
functional and behavioral competencies based on three staff levels: “evidence collectors 
and gatherers”, “evidence processors and distillers” and “decision makers”.⁹  Search 
results for “pharmacovigilance training” returned a number of results, of which two 
publications were applicable. Lynn et. al. describes a new post-graduate qualification in 
pharmacovigilance from the Drug Safety Research Unit in the UK.²⁰  Training unit topics 
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include drug safety sciences, including an introduction to pharmacoepidemiology and 
regulations and guidelines.²⁰. A Google scholar literature search yielded one article from 
Perspectives in Clinical Research: “Training in post-authorization pharmacovigilance”, 
which categorizes general and specific topics for pharmacovigilance employees in 
support of set up and maintenance of a post-authorization pharmacovigilance 
department.¹   
 Utilizing the Core Competencies for Public Heath Professionals²⁸ as a model and 
starting point for development of core competencies in the field of drug safety, Table 1 
proposes Drug Safety/Pharmacovigilance Core Competencies which describe the drug 
safety sciences knowledge that is necessary for competent performance as a drug 
safety professional. Table 2 proposes Drug Safety/Pharmacovigilance Core 
Competencies skill sets that support application and implementation of drug safety 
sciences knowledge, including analytical/assessment skills sets, communication skills, 
and leadership and systems thinking skills. These Core Competencies are not 
considered to be an all-inclusive list of desirable skills and traits, but rather to serve as a 
core model for development of drug safety professional training programs and 
professional development programs.  
 Similar standardization and acceptance of core competencies for drug safety 
professionals may increase the consistency of the practice of pharmacovigilance 
activities as well as enable drug safety professionals to broaden their skills sets and 
identify and fill any gaps in knowledge. In addition, acceptance of core competencies in 
support of the science of drug safety may enable stakeholders, such as practicing 
health care professionals including pharmacists and physicians, to better identify their 
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role and increase their involvement in the practice of pharmacovigilance through focus 
on both prevention and identification of adverse drug effects. 
 The Core Competencies for drug safety professionals are a set of skills 
applicable to the broad field of pharmacovigilance. Level 1 core competencies apply to 
entry level drug safety professionals, i.e. new drug safety associates with non-
managerial positions. Level 2 core competencies apply to advanced and senior level 
drug safety associates, supervisors and managers. Level 3 core competencies apply to 
associate directors, directors, and other drug safety department or organization leaders. 
Table 1: Drug Safety/Pharmacovigilance Core Competencies 
Knowledge of Drug Safety Sciences 
Level 1 Level 2 Level 3 
Identifies prominent events 
in the history of drug safety 
Distinguishes prominent 
events in the history of drug 
safety 
Describes lessons learned from 
prominent events in the history of 
drug safety and application to the 
current field 
Basic knowledge of 
national and international 
drug safety regulations, 
terminology and guidance 
documents. 
 
Interprets and applies 
national and international 
drug safety regulations, 
terminology and guidance 
documents to daily workflow. 
Provides training on drug 
safety regulations, 
terminology and guidance 
documents to Level 1 
professionals. 
Incorporates drug safety 
regulations and guidance 
documents into decision making, 
departmental infrastructure, 
standard operations, and metrics 
tracking. Provides feedback to 
regulators on draft regulations 
and draft guidance documents. 
Provides training on drug safety 
regulations, terminology and 
guidance documents to Level 1 
and Level 2 professionals.  
Basic knowledge of drug 
safety sciences (e.g. 
pharmacoepidemiology, 
pharmacogenomics). 
Applies the basic drug safety 
sciences (e.g. 
pharmacoepidemiology, 
pharmacogenomics) to the 
practice of drug safety. 
Applies the basic drug safety 
sciences (e.g. 
pharmacoepidemiology, 
pharmacogenomics) to the 
practice of drug safety. 
Basic knowledge of 
medical terminology, 
pharmacology, or clinical 
background. 
Advanced knowledge of 
medical terminology, 
pharmacology, or clinical 
background/experience. 
Advanced application of medical 
terminology, pharmacology, or 
clinical background/experience to 
the field of drug safety. 
Basic knowledge of the 
cycle of drug development. 
Advanced knowledge of the 
cycle of drug development. 
Advanced knowledge of the cycle 
of drug development. 
Knowledge of the standard 
components of an 
Knowledge and application of 
safety standards to writing of 
Knowledge and application of 
safety standards to writing ICSR 
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individual case safety 
report (ICSR) case 
narrative.  Ability to write 
an ICSR narrative. 
CSR case narratives, safety 
sections of study protocols, 
clinical study reports, annual 
and bi-annual safety reports, 
investigator brochures, and 
integrated summaries of 
safety.  
case narratives, safety sections 
of clinical study reports, annual 
and bi-annual safety reports, 
investigator brochures, and 
integrated summaries of safety. 
Basic knowledge of risk/ 
benefit analysis and 
components.  
Advanced knowledge of risk/ 
benefit analysis and practical 
application. Creation and 
maintenance of risk 
evaluation mitigation 
strategies (REMS) and risk 
management plans (RMPs).  
Advanced knowledge of risk/ 
benefit analysis and practical 
application. Creation and 
maintenance of risk evaluation 
mitigation strategies (REMS) and 
risk management plans (RMPs). 
Management of REMS/RMPs for 
marketed products. 
Basic knowledge of signal 
detection functions. 
Advanced knowledge and 
application of signal detection 
functions, including regular 
review of AE listings and data 
mining. 
Advanced knowledge and 
application of signal detection 
functions, including regular 
review of AE listings and data 
mining. 
 Contributes to building the 
scientific evidence base of 
drug safety 
Contributes to building the 
scientific evidence base of drug 
safety 
 
 
Table 2: Drug Safety/Pharmacovigilance Core Competencies 
Skill Sets 
2A: Analytical/Assessment Skills 
Level 1 Level 2 Level 3 
Employs ethical principles 
in the collection, 
maintenance, use and 
dissemination of safety 
data and protected health 
information. 
Employs ethical principles in 
the collection, maintenance, 
use and dissemination of 
safety data and protected 
health information. 
Employs ethical principles in the 
collection, maintenance, use and 
dissemination of safety data and 
protected health information. 
Basic knowledge of data 
entry, quality control, 
coding, workflow, and 
report-producing 
procedures within validated 
safety databases 
Advanced knowledge of 
coding, workflow and report-
producing procedures within 
validated safety databases. 
Oversight of data entry and 
quality control procedures by 
Level 1 and other support 
employees. Participation in 
safety database validation 
and user acceptance testing. 
Advanced knowledge of safety 
database validation procedures, 
database upgrades, database 
change orders, database 
migrations, and interactions with 
IT validation personnel and 
database administrator.  
Advanced application of safety 
database workflow tools to daily 
case processing by Level 1 and 
Level 2 professionals.   
Basic knowledge of 
adverse event 
expectedness/labeling  
Advanced knowledge and 
application of adverse event 
expectedness/labeling 
Advanced knowledge and 
application of adverse event 
expectedness/labeling 
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assessments and labeling 
documentation 
assessments and labeling 
documentation. Participation 
in writing of labeling 
documents, including 
Investigator Brochures, 
package inserts, summary of 
product characteristics 
assessments and labeling 
documentation. Participation in 
writing of labeling documents, 
including Investigator Brochures, 
package inserts, summary of 
product characteristics 
Basic knowledge of 
components of causality  
determination (i.e. temporal 
relationship, concomitant 
medical history and 
medication) 
Advanced knowledge of 
components of causality 
determination. Interacts with 
medical monitors for 
company causality 
assessments. 
Advanced knowledge of 
components of causality 
determination. Trains medical 
monitors regarding company 
causality assessments. 
Basic knowledge and 
practice of due diligence 
(i.e. queries for follow-up 
information) in case 
processing. 
Advanced understanding and 
application of due diligence in 
case processing. 
Ensure quality application of due 
diligence in case processing by 
staff (level 1, level 2). 
Basic knowledge of study 
protocols for clinical safety 
Advanced application of study 
protocol knowledge to SAE 
report processing, i.e. 
recognize and report to study 
team inclusion/exclusion 
violations. Trains Level 1 staff 
on new study protocols. 
Trains Level 1 and Level 2 
professionals on new study 
protocols. 
Basic knowledge and 
understanding of MedDRA 
coding dictionary 
Advanced knowledge and 
application of commercial 
coding dictionaries (MedDRA, 
WHO-Drug), provides 
oversight and feedback on 
adverse event and drug 
coding 
Advanced knowledge and 
application of commercial coding 
dictionaries (MedDRA, WHO-
Drug), provides feedback to 
commercial coding dictionary 
vendors, to improve content and 
mapping  
Computer application 
proficiency (MS Word, MS 
Excel, MS Powerpoint, 
web-based) for access and 
entry of safety information. 
Computer application 
expertise (MS Word, MS 
Excel, MS Powerpoint, web-
based) for safety information 
tracking, assessment 
information, reconciliation, 
and metrics.  
Computer application expertise 
(MS Word, MS Excel, MS 
Powerpoint, web-based) for 
safety information tracking, 
assessment information, 
reconciliation, and metrics. 
Basic knowledge of 
electronic data capture 
(EDC) systems in order to 
enter and retrieve safety 
data. 
Advanced knowledge of 
electronic data capture 
systems in order to provide 
specifications to 
programmers for adverse 
event reporting and serious 
adverse event reporting 
panels, specifications for 
system verification checks, 
and specifications for safety 
reports and transfers.  
Ensures other functional 
departments include Safety in 
development of new EDC 
systems in order to maintain 
compliance with safety 
regulations and reporting 
timelines. 
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2B: Communication Skills 
Level 1 Level 2 Level 3 
Communicates in writing 
and orally, in person, and 
through e-mail with 
linguistic proficiency and 
cultural sensitivity. 
Communicates in writing and 
orally, in person, and through 
e-mail with linguistic 
proficiency and cultural 
sensitivity. 
Communicates in writing and 
orally, in person, and through e-
mail with linguistic proficiency and 
cultural sensitivity. 
Communicates with 
(adverse event) reporters 
and investigative sites in a 
professional manner. 
Communicates with (adverse 
event) reporters, investigative 
sites, sponsors, departmental  
contacts, study project 
managers, clinical research 
associates (CRAs), study 
vendors, data safety and 
monitoring boards (DSMBs), 
and auditors in a professional 
manner. 
Communicates with sponsors, 
functional departmental heads, 
study vendors, data safety and 
monitoring boards (DSMBs), 
auditors, and health authorities in 
a professional manner. 
Applies communication 
and group dynamic 
strategies in interactions 
with individuals and groups 
Applies communication and 
group dynamic strategies in 
interactions with individuals 
and groups 
Applies communication and 
group dynamic strategies in 
interactions with individuals and 
groups 
Audience member of drug 
safety presentations 
Develops and delivers 
presentations on drug safety 
topics, including training 
investigative sites and study 
teams on new safety 
reporting protocols, 
presentations at professional 
conferences and other 
venues. 
Develops, delivers and provides 
feedback on presentations on 
drug safety topics, including 
presentations at professional 
conferences and other venues. 
Reads scientific 
publications relevant to 
drug safety. 
Reads scientific publications 
relevant to drug safety and 
applies knowledge to daily 
work. 
Applies evidence-based drug 
safety practices to safety 
operations. 
Publishes on drug safety topics. 
 
2C: Leadership and Systems Thinking Skills 
Level 1 Level 2 Level 3 
Performs timely 
coordination of safety 
information dissemination. 
Practices effective pro-active 
decision-making with timely 
coordination of safety 
information dissemination. 
Promotes and practices effective 
pro-active decision-making. 
Ensures timely coordination of 
safety information dissemination. 
Incorporates ethical 
standards of practice as 
the basis of all interactions 
with sponsors, vendors, 
consumers, health care 
professionals, other 
Incorporates ethical 
standards of practice as the 
basis of all interactions with 
sponsors, vendors, 
consumers, health care 
professionals, other functional 
Incorporates ethical standards of 
practice as the basis of all 
interactions with sponsors, 
vendors, consumers, health care 
professionals, other functional 
groups, health authorities, 
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functional groups, health 
authorities, auditors and 
other drug safety 
stakeholders. 
groups, health authorities, 
auditors and other drug safety 
stakeholders. 
auditors and other drug safety 
stakeholders. 
Describes how 
pharmacovigilance 
department operates within 
a larger system. 
Incorporates systems thinking 
into the practice of 
pharmacovigilance. 
Incorporates systems thinking 
into the practice of 
pharmacovigilance. 
Ability to follow written 
documentation in support 
of pharmacovigilance 
activities, including 
standard operating 
procedures (SOPs), safety 
management plans and 
working instructions. 
Ability to follow written 
documentation in support of 
pharmacovigilance activities. 
Ability to develop various 
levels of documentation in 
support of pharmacovigilance 
department functions, 
including standard operating 
procedures, safety 
management plans, and 
working instructions. 
Ability to develop and implement 
various levels of documentation 
in support of pharmacovigilance 
department functions, including 
standard operating procedures, 
safety management plans, and 
working instructions.  
Ensure staff compliance with 
pharmacovigilance department 
documentation.  
 
Participates in measuring, 
tracking and reporting 
activities that contribute to 
continuous quality 
improvement (CQI) of 
departmental and 
organizational 
performance. 
Participates in measuring, 
tracking, and reporting 
activities that continuous 
quality improvement (CQI) of 
departmental and 
organizational performance. 
Ensures the measuring, reporting 
and continuous quality 
improvement (CQI) of 
departmental and organizational 
performance. 
Basic knowledge of 
interdepartmental 
standards and business 
practices. 
Participates in cross-
functional collaboration and 
development of 
interdepartmental standards, 
and business practices. 
Promotes and ensures cross-
functional team collaborations 
and interdepartmental standards 
and business practices. 
Attends project team and 
departmental meetings and 
provides safety status 
updates. 
Attends and leads project 
team and departmental 
meetings. 
 
Attends and leads program team, 
departmental and organizational 
meetings.  
Performs safety activities 
for safety projects 
according to contract and 
budget parameters. 
Provides input to safety 
project contracts and 
budgets. 
Manages safety projects 
within current and forecasted 
budget constraints. 
Develops budgets, proposals, 
and contracts for safety projects.  
Ensures that safety projects are 
managed within current and 
forecasted budget constraints. 
Attends individual, team 
and organizational learning 
opportunities for 
professional development. 
Promotes and attends 
individual, team and 
organizational learning 
opportunities. 
Advocates for individual, team 
and organizational learning 
opportunities. 
Participates in mentoring 
and peer review or 
coaching opportunities 
Performs mentoring, peer 
advising, coaching, or other 
professional development 
opportunities for 
Establishes mentoring, peer 
advising, coaching, or other 
professional development 
opportunities for 
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pharmacovigilance 
department staff 
pharmacovigilance department 
staff 
Receives regular 
performance evaluation 
and feedback. 
Performs and receives 
regular performance 
evaluation and feedback 
to/from staff. 
Ensures regular performance 
evaluation and feedback for staff. 
 
Conclusion:   
 While advances in pharmacovigilance with the emergence of the science of 
safety and the availability of increasingly powerful information technologies allow the 
FDA to more actively monitor the safety of marketed drugs through data mining of 
electronic health records and collaborations with various members of the public and 
privates sectors, stakeholders need to be cognizant that the safety of patients is a 
shared responsibility.³³ Along with the need for healthcare professionals to detect and 
prevent adverse events in their patients, there is need for consumers to advocate for 
themselves, armed with information of the potential for adverse drug effects and how to 
report adverse events. Development of evidence-based objective-driven public 
pharmacovigilance communication strategies are in order.² Pharmaceutical and 
biotechnology sponsors should pro-actively address the need for a competent and 
contemporary pharmacovigilance work force, through adoption of pharmacovigilance 
core competencies as the basis for developing expertise in the field of drug safety and 
in order to contribute to building the scientific evidence-base of drug safety.  
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Appendices 
Appendix 1: Drug safety definitions and terminology  
Adverse 
drug 
reaction 
(ADR) 
All noxious and unintended responses to a medicinal product related to any dose should 
be considered adverse drug reactions.  
 
The phrase "responses to a medicinal product" means that a causal relationship between a 
medicinal product and an adverse event is at least a reasonable possibility, i.e., the 
relationship cannot be ruled out.  
Regarding marketed medicinal products, a well-accepted definition of an adverse drug 
reaction in the post-marketing setting is found in WHO Technical Report 498 [1972] and 
reads as follows:  
A response to a drug which is noxious and unintended and which occurs at doses normally 
used in man for prophylaxis, diagnosis, or therapy of disease or for modification of 
physiological function.  
(ICH E2A) 
Adverse 
event (AE) 
Adverse event means any untoward medical occurrence associated with the use of a drug 
in humans, whether or not considered drug related. (FDA CFR 312.32) 
Adverse event: Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product and which does not necessarily have to 
have a causal relationship with this treatment.  
An adverse event (AE) can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding, for example), symptom, or disease temporally associated with 
the use of a medicinal product, whether or not considered related to the medicinal product. 
(ICH E2A) 
CFR Code of Federal Regulations 
CIOMS Council for International Organizations of Medical Sciences 
DMC/DSMB Data Monitoring Committee/Data Safety and Monitoring Board 
FDA US Food and Drug Administration 
IB/IDB Investigators (Drug) Brochure 
ICH International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use 
IND Investigational New Drug Application 
IND Safety 
Report 
The sponsor must notify FDA and all participating investigators (i.e., all investigators to 
whom the sponsor is providing drug under its INDs or under any investigator's IND) in an 
IND safety report of potential serious risks, from clinical trials or any other source, as soon 
as possible, but in no case later than 15 calendar days after the sponsor determines that 
the information qualifies for reporting under paragraph (c)(1)(i), (c)(1)(ii), (c)(1)(iii), or 
(c)(1)(iv) of this section. In each IND safety report, the sponsor must identify all IND safety 
reports previously submitted to FDA concerning a similar suspected adverse reaction, and 
must analyze the significance of the suspected adverse reaction in light of previous, similar 
reports or any other relevant information.   
(i) Serious and unexpected suspected adverse reaction. The sponsor must report any 
suspected adverse reaction that is both serious and unexpected. The sponsor must report 
an adverse event as a suspected adverse reaction only if there is evidence to suggest a 
causal relationship between the drug and the adverse event, such as: 
(A) A single occurrence of an event that is uncommon and known to be strongly associated 
with drug exposure (e.g., angioedema, hepatic injury, Stevens-Johnson Syndrome); 
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(B) One or more occurrences of an event that is not commonly associated with drug 
exposure, but is otherwise uncommon in the population exposed to the drug (e.g., tendon 
rupture); 
(C) An aggregate analysis of specific events observed in a clinical trial (such as known 
consequences of the underlying disease or condition under investigation or other events 
that commonly occur in the study population independent of drug therapy) that indicates 
those events occur more frequently in the drug treatment group than in a concurrent or 
historical control group. 
(ii) Findings from other studies. The sponsor must report any findings from epidemiological 
studies, pooled analysis of multiple studies, or clinical studies (other than those reported 
under paragraph (c)(1)(i) of this section), whether or not conducted under an IND, and 
whether or not conducted by the sponsor, that suggest a significant risk in humans 
exposed to the drug. Ordinarily, such a finding would result in a safety-related change in 
the protocol, informed consent, investigator brochure (excluding routine updates of these 
documents), or other aspects of the overall conduct of the clinical investigation. 
(iii) Findings from animal or in vitro testing. The sponsor must report any findings from 
animal or in vitro testing, whether or not conducted by the sponsor, that suggest a 
significant risk in humans exposed to the drug, such as reports of mutagenicity, 
teratogenicity, or carcinogenicity, or reports of significant organ toxicity at or near the 
expected human exposure. Ordinarily, any such findings would result in a safety-related 
change in the protocol, informed consent, investigator brochure (excluding routine updates 
of these documents), or other aspects of the overall conduct of the clinical investigation. 
(iv) Increased rate of occurrence of serious suspected adverse reactions. The sponsor 
must report any clinically important increase in the rate of a serious suspected adverse 
reaction over that listed in the protocol or investigator brochure. (FDA CFR 312.32) 
 
Serious 
adverse 
event or 
serious 
suspected 
adverse 
reaction 
(SAE or 
SSAR) 
 
Serious adverse event or serious suspected adverse reaction. An adverse event or 
suspected adverse reaction is considered “serious” if, in the view of either the investigator 
or sponsor, it results in any of the following outcomes: Death, a life-threatening adverse 
event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or 
significant incapacity or substantial disruption of the ability to conduct normal life functions, 
or a congenital anomaly/birth defect. Important medical events that may not result in death, 
be life-threatening, or require hospitalization may be considered serious when, based upon 
appropriate medical judgment, they may jeopardize the patient or subject and may require 
medical or surgical intervention to prevent one of the outcomes listed in this definition. 
Examples of such medical events include allergic bronchospasm requiring intensive 
treatment in an emergency room or at home, blood dyscrasias or convulsions that do not 
result in inpatient hospitalization, or the development of drug dependency or drug abuse. 
(FDA CFR 312.32) 
 
‘serious adverse event or serious adverse reaction’: any untoward medical occurrence or 
effect that at any dose results in death, is life-threatening, requires hospitalization or 
prolongation of existing hospitalisation, results in persistent or significant disability or 
incapacity, or is a congenital anomaly or birth defect (Directive 2001/20/EC) 
Suspected 
adverse 
reaction 
Suspected adverse reaction means any adverse event for which there is a reasonable 
possibility that the drug caused the adverse event. For the purposes of IND safety 
reporting, “reasonable possibility” means there is evidence to suggest a causal relationship 
between the drug and the adverse event. Suspected adverse reaction implies a lesser 
degree of certainty about causality than adverse reaction, which means any adverse event 
caused by a drug. (FDA CFR 312.32) 
Unexpected An adverse reaction, the nature or severity of which is not consistent with the applicable 
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Adverse 
Drug 
Reaction 
product information (e.g., Investigator's Brochure for an unapproved investigational 
medicinal product). (ICH E2A) 
Unexpected 
adverse 
event or 
unexpected 
suspected 
adverse 
reaction 
Unexpected adverse event or unexpected suspected adverse reaction. An adverse event 
or suspected adverse reaction is considered “unexpected” if it is not listed in the 
investigator brochure or is not listed at the specificity or severity that has been observed; 
or, if an investigator brochure is not required or available, is not consistent with the risk 
information described in the general investigational plan or elsewhere in the current 
application, as amended. For example, under this definition, hepatic necrosis would be 
unexpected (by virtue of greater severity) if the investigator brochure referred only to 
elevated hepatic enzymes or hepatitis. Similarly, cerebral thromboembolism and cerebral 
vasculitis would be unexpected (by virtue of greater specificity) if the investigator brochure 
listed only cerebral vascular accidents. “Unexpected,” as used in this definition, also refers 
to adverse events or suspected adverse reactions that are mentioned in the investigator 
brochure as occurring with a class of drugs or as anticipated from the pharmacological 
properties of the drug, but are not specifically mentioned as occurring with the particular 
drug under investigation. (FDA CFR 312.32) 
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